Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azacitidine
Drug ID BADD_D00194
Description A pyrimidine nucleoside analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.
Indications and Usage For treatment of patients with the following French-American-British myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation (now classified as acute myelogenous leukemia with multilineage dysplasia), and chronic myelomonocytic leukemia.
Marketing Status Prescription
ATC Code L01BC07
DrugBank ID DB00928
KEGG ID D03021
MeSH ID D001374
PubChem ID 9444
TTD Drug ID D09FAZ
NDC Product Code 43598-678; 59572-740; 16729-306; 71288-115; 16714-927; 0781-3253; 43598-305; 71288-153; 63592-1800; 68001-313; 63759-0015; 67457-254; 59572-730; 70121-1237; 68001-527; 72606-558; 69097-805; 69097-368; 0781-9253; 59572-102; 64679-096; 68554-0104; 66529-0013; 63660-0010; 14096-121; 51991-797; 42385-719; 63323-771; 51916-350; 68001-504; 65129-1222; 72485-201; 43598-465; 53183-4011; 0143-9606; 43817-906; 54893-0029
Synonyms Azacitidine | 5-Azacytidine | 5 Azacytidine | Azacytidine | Vidaza | NSC-102816 | NSC 102816 | NSC102816
Chemical Information
Molecular Formula C8H12N4O5
CAS Registry Number 320-67-2
SMILES C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abscess jaw11.01.01.005; 15.02.05.0040.000533%Not Available
Urinary tract infection bacterial20.08.02.006; 11.02.01.0240.000533%Not Available
Clostridium difficile infection11.02.02.009--Not Available
Hepatic infection11.01.18.008; 09.01.08.0140.000533%
Bone marrow necrosis01.05.01.012; 24.04.09.0020.000208%Not Available
Acute myeloid leukaemia recurrent16.01.05.004; 01.10.05.0040.003753%Not Available
Scedosporium infection11.03.05.0290.000139%Not Available
Escherichia infection11.02.10.0040.001332%Not Available
Klebsiella infection11.02.03.0030.000799%Not Available
Traumatic intracranial haemorrhage24.07.04.034; 17.08.05.005; 12.01.10.0170.000139%Not Available
Blast cell count increased13.01.03.0080.001042%Not Available
Leukaemia recurrent16.01.03.005; 01.10.03.0050.000556%Not Available
Graft versus host disease in skin23.07.04.025; 12.02.09.031; 10.02.01.0620.001066%Not Available
Graft versus host disease in liver12.02.09.029; 10.02.01.060; 09.01.07.0330.001598%Not Available
Middle ear inflammation04.05.01.0060.000139%
Central nervous system leukaemia17.02.10.019; 16.01.03.004; 01.10.03.0040.000208%Not Available
Acute graft versus host disease in intestine12.02.09.020; 10.02.01.051; 07.11.01.0190.000799%Not Available
Neutrophilic panniculitis23.07.02.0040.000533%Not Available
Acute lung injury22.01.03.0100.000139%Not Available
Acquired gene mutation08.01.10.0020.000533%Not Available
Epstein-Barr virus associated lymphoma16.28.01.003; 11.05.10.007; 01.15.01.0030.000139%Not Available
Chronic graft versus host disease in skin10.02.01.057; 23.07.04.022; 12.02.09.0250.000533%Not Available
Graft versus host disease in gastrointestinal tract12.02.09.028; 10.02.01.059; 07.11.01.0270.000625%Not Available
Internal haemorrhage24.07.01.0720.001066%Not Available
Blastic plasmacytoid dendritic cell neoplasia23.07.04.021; 16.20.01.004; 01.12.01.0040.000208%Not Available
The 24th Page    First    Pre   24    Total 24 Pages